Meds & supplements › Siltuximab
Medicine · Interleukin-6 Antagonist
Siltuximab
SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
- Do not take if
- Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.
- Hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab.
Side effects, and when to stop
The following clinically significant adverse reactions are also discussed in other sections of the labeling:
- Concurrent active severe infections
- Infusion-related reactions and hypersensitivity
- Gastrointestinal perforation
Who should not take it
Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT. Hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab.
Storing it
SYLVANT must be refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not use SYLVANT beyond the expiration date (EXP) located on the carton and the vial.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Siltuximab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/siltuximab
- APA 7th
sofidex. (2026, August 3). Siltuximab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/siltuximab
- AMA 11th
Siltuximab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/siltuximab
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.